Page 6 - Pharmaceutical Companies

China-Plus-One strategy: Indian API firms start to reap benefits

Rising Chinese labour costs, geopolitics, pandemic-stricken uncertainties have forced global players to derisk

Top Headlines: Oz parliament okays FTA with India, RBI rate hike & more

The Australian Parliament on Monday ratified the Economic Cooperation and Trade Agreement (ECTA) with India, paving the way for implementing the deal as early as January 1, 2023

World in turmoil, domestic pharma firms target India for healthy growth

Share of India revenue in home-grown firms' consolidated turnover rising over the years

Inflows in Tata Motors stock may surge as it replace Dr Reddy's in Sensex

Change effective from Dec 19, but adjustment will take place on Dec 16. After DRL's deletion, Sun Pharma will be the only healthcare stock in the index

Trying to lock in vendors who don't want to buy from China: Biocon CEO & MD

Siddharth Mittal, CEO & MD, Biocon, elaborates on his plans to grow this business further

Sun Pharma's Mohali plant in Punjab receives OAI status from USFDA

The plant was inspected in August and had received a form 483 with six observations earlier

Cipla Q2 PAT up 11% PAT to Rs 789 cr on strong Covid-adjusted growth rate

The company is de-risking key product Abraxane in case the Goa plant FDA issue is not cleared immediately

India looking at greater market access for pharma products in UK under FTA

India is looking at greater market access for its pharmaceutical products in the UK as part of the proposed free trade agreement with Britain, an official said on Friday. The official also said that a leaked chapter of the agreement, which is floated on some portals, on intellectual property (IP) is edited, distorted, and is a manipulated version of an initial document of the UK. "The best part in the proposed agreement is that both sides have highlighted their red lines and sensitivities. Ever-greening and touching manufacturing of generic medicines is completely non-negotiable," the official added. India has already secured greater market access for the domestic pharma industry in a trade pact with the UAE. Under the pact, Indian pharmaceutical products and medical goods will get regulatory approval within 90 days that have been approved in developed jurisdictions such as the US, the UK, the EU, Canada, and Australia. Similarly, the India-Australia trade deal would provide ...

Chhattisgarh govt's flagship scheme delivers hefty markdown on medicines

The state government has given priority to the health security of the people, the official said

Sun Pharma Q2 PAT rises 10.5% YoY to Rs 2,262 crore on robust sales

Gross sales came in at Rs 10,809.2 crore, growing by 13.1% over Q2 last year

Q2FY23 preview: Modest revenue growth, Ebitda decline seen in pharma cos

While domestic market demand is strong, analysts expect higher raw material and freight costs to affect business in US, other countries; healthy YoY growth seen in hospitals and diagnostics

Drug regulator halts production at Maiden Pharma's Sonipat unit

Centre forms panel to analyse causal relation between deaths and cough syrups

Haryana stops production at plant making cough syrups flagged by WHO

12 violations found at Maiden Pharmaceuticals' Sonipat facility, says state health minister

Gambia police link child deaths to cough syrup imported by US firm

The deaths of 69 children from acute kidney injury in Gambia is linked to four cough syrups made in India and imported into the West African country via a US-based pharma firm, the Gambian police said

Maiden Pharma's cough syrups, under WHO scanner, not sold in India: Sources

Meanwhile, the Indian regulator is awaiting evidence of links between the cough syrups and the deaths in Gambia

Existing pharma marketing practices code is adequate: Centre tells SC

Says Indian Pharmaceutical Alliance's investigation report cleared Dolo-650 maker, Micro Labs, of allegations of bribing doctors with freebies worth Rs 1,000 crore

Pharma industry says taking steps to check misuse of codeine drugs

Sales declining anyway and there is no need to ban because of alleged misuse, say experts

DTAB to review 19 fixed-dose combinations drugs, codeine formulations today

CDSCO aims to phase out these combinations and codeine-based drugs in a phased manner

Hospital chains abused their dominance to charge exorbitant prices: Report

A CCI investigation showed that higher pricing was charged for renting rooms, medicines, tests, medical devices, and consumables. In some hospitals, the room rents exceeded charges of 4-star hotels

India sets up export promotion council for medical devices under DoP

India currently exports Rs. 23,766 crore (2021-22) of medical devices up from previous year Rs 19,736 crore